Dominic Muston
Overview
Explore the profile of Dominic Muston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monk B, van Mens S, Hale O, Boer J, van Hees F, Swami S, et al.
Oncol Ther
. 2024 Nov;
13(1):85-98.
PMID: 39499492
Introduction: First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides...
2.
Muston D
Appl Health Econ Health Policy
. 2024 May;
22(5):619-628.
PMID: 38771430
The characteristics and relative strengths and weaknesses of partitioned survival models (PSMs) and state transition models (STMs) for three state oncology cost-effectiveness models have previously been studied. Despite clear and...
3.
Agnihotri N, Ambavane A, Fan L, Li W, Yoo H, Joo S, et al.
Pancreatology
. 2024 Jan;
24(2):271-278.
PMID: 38286712
Background: Germline BRCA mutations (gBRCAm) occur in 4%-8% patients with metastatic pancreatic cancer (mPC); guidelines recommend platinum-based chemotherapies and olaparib maintenance in this population. We evaluated, through modeling, the role...
4.
Elsea D, Muston D, Fan L, Mihai A, Meng Y, Kasle A, et al.
Target Oncol
. 2023 May;
18(4):531-541.
PMID: 37233868
Background: Poly(ADP-ribose) polymerase inhibitor maintenance treatments are available for platinum-sensitive advanced ovarian cancer. Olaparib (O) is available for BRCA mutation patients or in combination with bevacizumab (O+B) for patients with...
5.
Elsea D, Fan L, Mihai A, El Moustaid F, Simmons D, Monberg M, et al.
Pharmacoecon Open
. 2022 Sep;
6(6):899.
PMID: 36107308
No abstract available.
6.
Elsea D, Fan L, Mihai A, El Moustaid F, Simmons D, Monberg M, et al.
Pharmacoecon Open
. 2022 Aug;
6(6):811-822.
PMID: 36036344
Background: In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to platinum-based chemotherapy in homologous recombination deficiency (HRD)-positive ovarian cancer. Our study evaluated...
7.
Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla J, et al.
J Mark Access Health Policy
. 2022 Jun;
10(1):2078474.
PMID: 35693379
Background: The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated. Objective: Compare PARPi-related AE management costs...
8.
Evans R, Hawkins N, Dequen-OByrne P, McCrea C, Muston D, Gresty C, et al.
Target Oncol
. 2021 Sep;
16(5):613-623.
PMID: 34478046
Background: In oncology trials, treatment switching from the comparator to the experimental regimen is often allowed but may lead to underestimating overall survival (OS) of an experimental therapy. Objective: This...
9.
Muston D, Hettle R, Monberg M, McLaurin K, Gao W, Swallow E, et al.
Gynecol Oncol
. 2020 Sep;
159(2):491-497.
PMID: 32951894
Objective: This study evaluated the cost-effectiveness of olaparib monotherapy in the first-line maintenance setting vs. surveillance in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation from a...
10.
Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, et al.
Pharmacoeconomics
. 2020 Aug;
38(11):1201-1218.
PMID: 32794041
Background: Ovarian cancer is the fifth leading cause of cancer death in women in the US. With poly(ADP-ribose) polymerase (PARP) inhibitors having shown promising results in ongoing trials, there is...